• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Metastatic Renal Cell Cancer-Systemic Therapy.转移性肾细胞癌——全身治疗
Indian J Surg Oncol. 2018 Mar;9(1):97-104. doi: 10.1007/s13193-018-0721-2. Epub 2018 Jan 29.
2
Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting.一线治疗中仅使用可用的舒尼替尼和帕唑帕尼治疗的转移性肾细胞癌患者的真实世界总生存期
Front Oncol. 2022 Jun 8;12:892156. doi: 10.3389/fonc.2022.892156. eCollection 2022.
3
Management and Health Resource Use of Patients With Metastatic Renal Cell Carcinoma treated With Systemic Therapy Over 2014-2017 in France: A National Real-World Study.2014-2017 年法国接受系统治疗的转移性肾细胞癌患者的管理和卫生资源利用：一项全国真实世界研究。
Clin Genitourin Cancer. 2022 Dec;20(6):533-542. doi: 10.1016/j.clgc.2022.07.010. Epub 2022 Jul 24.
4
Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.靶向治疗在转移性肾细胞癌患者中的应用：加拿大真实临床环境中的临床和经济影响
Curr Oncol. 2018 Dec;25(6):e576-e584. doi: 10.3747/co.25.4103. Epub 2018 Dec 1.
5
First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience.转移性肾细胞癌的一线酪氨酸激酶抑制剂：一个地区癌症中心的经验
Indian J Cancer. 2017 Oct-Dec;54(4):626-630. doi: 10.4103/ijc.IJC_380_17.
6
Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.治疗初治转移性肾细胞癌的系统治疗：基于风险的方法。
Expert Opin Pharmacother. 2010 Oct;11(14):2351-62. doi: 10.1517/14656566.2010.499126.
7
Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.原发灶不明的癌（CUP）合并转移性肾细胞癌（mRCC）组织学和免疫组织化学特征（CUP-mRCC）：接受靶向治疗的连续患者的结果和文献复习。
Clin Genitourin Cancer. 2019 Feb;17(1):e32-e37. doi: 10.1016/j.clgc.2018.08.005. Epub 2018 Aug 28.
8
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.在英国，接受靶向系统治疗的转移性肾细胞癌患者的治疗模式和健康结果。
BMC Cancer. 2020 Jul 17;20(1):670. doi: 10.1186/s12885-020-07154-z.
9
Systemic therapy in metastatic renal cell carcinoma.转移性肾细胞癌的全身治疗
World J Urol. 2017 Feb;35(2):179-188. doi: 10.1007/s00345-016-1868-5. Epub 2016 Jun 9.
10
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.已获批的一线抗血管生成和分子靶向治疗药物在治疗低危和中危转移性透明细胞肾细胞癌中的疗效比较
BMC Cancer. 2014 Aug 15;14:592. doi: 10.1186/1471-2407-14-592.

引用本文的文献

1
Clear Cell Renal Cell Carcinoma Spinal Metastases: Which Factors Matter to the Overall Survival? A 10-Year Experience of a High-Volume Tumor Spine Center.透明细胞肾细胞癌脊柱转移：哪些因素对总生存期有影响？一家高容量肿瘤脊柱中心的10年经验。
Diagnostics (Basel). 2022 Oct 9;12(10):2442. doi: 10.3390/diagnostics12102442.

本文引用的文献

1
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.卡博替尼与依维莫司治疗晚期肾细胞癌的疗效对比
N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.
2
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.纳武单抗与依维莫司治疗晚期肾细胞癌的比较
N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
3
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).BEST：血管内皮生长因子、RAF激酶和雷帕霉素哺乳动物靶点联合靶向治疗（贝伐单抗、索拉非尼和替西罗莫司）用于晚期肾细胞癌的随机II期研究——东部肿瘤协作组-美国放射肿瘤学会癌症研究组（E2804）试验
J Clin Oncol. 2015 Jul 20;33(21):2384-91. doi: 10.1200/JCO.2015.60.9727. Epub 2015 Jun 15.
4
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.比较依维莫司一线序贯治疗联合舒尼替尼二线治疗与舒尼替尼一线治疗联合依维莫司二线治疗转移性肾细胞癌患者的 II 期随机试验。
J Clin Oncol. 2014 Sep 1;32(25):2765-72. doi: 10.1200/JCO.2013.54.6911. Epub 2014 Jul 21.
5
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.随机、对照、双盲、交叉试验评估转移性肾细胞癌患者对帕唑帕尼与舒尼替尼的治疗偏好：PISCES 研究。
J Clin Oncol. 2014 May 10;32(14):1412-8. doi: 10.1200/JCO.2013.50.8267. Epub 2014 Mar 31.
6
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.随机 III 期试验：替西罗莫司对比索拉非尼作为舒尼替尼治疗转移性肾细胞癌后的二线治疗。
J Clin Oncol. 2014 Mar 10;32(8):760-7. doi: 10.1200/JCO.2013.50.3961. Epub 2013 Dec 2.
7
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.阿昔替尼对比索拉非尼作为转移性肾细胞癌患者的一线治疗：一项随机开放标签的 3 期临床试验。
Lancet Oncol. 2013 Dec;14(13):1287-94. doi: 10.1016/S1470-2045(13)70465-0. Epub 2013 Oct 25.
8
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.阿昔替尼加或不加剂量滴定用于一线转移性肾细胞癌：一项随机双盲 2 期试验。
Lancet Oncol. 2013 Nov;14(12):1233-42. doi: 10.1016/S1470-2045(13)70464-9. Epub 2013 Oct 18.
9
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.帕唑帕尼对比舒尼替尼用于转移性肾细胞癌。
N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989.
10
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.阿昔替尼对比索拉非尼作为晚期肾细胞癌的二线治疗：一项随机 3 期临床试验的总生存分析及更新结果。
Lancet Oncol. 2013 May;14(6):552-62. doi: 10.1016/S1470-2045(13)70093-7. Epub 2013 Apr 16.

转移性肾细胞癌——全身治疗

Metastatic Renal Cell Cancer-Systemic Therapy.

作者信息

Joshi Amit, Sahu Arvind, Noronha Vanita, Patil Vijay, Prabhash Kumar

机构信息

Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.

出版信息

Indian J Surg Oncol. 2018 Mar;9(1):97-104. doi: 10.1007/s13193-018-0721-2. Epub 2018 Jan 29.

DOI:10.1007/s13193-018-0721-2
PMID:29563746
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5856703/
Abstract

Management of metastatic renal cell carcinoma (mRCC) has evolved considerably in the past 10 years due to better understanding of tumor biology. This development has changed mRCC to a chronic progressive disease with several lines of treatment options. The introduction of several new targeted therapies including immunotherapy has improved median overall survival of approximately 1 year to >2 years in mRCC.

摘要

由于对肿瘤生物学有了更深入的了解，转移性肾细胞癌（mRCC）的管理在过去10年中有了显著进展。这一进展已将mRCC转变为一种有多种治疗选择的慢性进展性疾病。包括免疫疗法在内的几种新靶向疗法的引入，已将mRCC的中位总生存期从约1年提高到了2年以上。